Wei, NJ
Carolyn S. Wei, New Brunswick, NJ US
Patent application number | Description | Published |
---|---|---|
20160022675 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES - Disclosed are processes for preparing tetrahydroisoquinolines, intermediates useful in the preparation of tetrahydroisoquinolines, processes for preparing such intermediates, and compositions comprising the tetrahydroisoquinolines and other compounds, e.g, intermediates and by-products of the processes described herein. Pharmaceutical compositions comprising tetrahydroisoquinolines, methods of using tetrahydroisoquinolines in the treatment of depression are also disclosed. | 01-28-2016 |
Chenkou Wei, Princeton, NJ US
Patent application number | Description | Published |
---|---|---|
20110257085 | Crystal Forms of Saxagliptin and Processes for Preparing Same - Physical crystal structures of a compound of the formula I: | 10-20-2011 |
20120283181 | CRYSTAL FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING SAME - Physical crystal structures of a compound of the formula I: | 11-08-2012 |
20140121155 | Crystal Forms of Saxagliptin and Processes for Preparing Same - Physical crystal structures of a compound of the formula I: | 05-01-2014 |
Chenkou Wei, Princeton Junction, NJ US
Patent application number | Description | Published |
---|---|---|
20080269499 | CRYSTALLINE FORMS AND PROCESS FOR PREPARING SPIRO-HYDANTOIN COMPOUNDS - A process is provided for preparing spiro-hydantoin compounds of the formula II | 10-30-2008 |
20090054303 | CRYSTAL FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING SAME - Physical crystal structures of a compound of the formula I: | 02-26-2009 |
20090093516 | TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS - Novel compounds are provided which are 11 -beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: | 04-09-2009 |
20100292250 | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- - TETRAHYDROISOQUINOLINE AND USE THEREOF - Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention. | 11-18-2010 |
20110288051 | TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS - Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: | 11-24-2011 |
20120302571 | CRYSTALLINE FORMS OF (S)-1-(4-(5-CYCLOPROPYL-1H-PYRAZOL-3-YLAMINO)PYRROLO[1,2-f][1,2,4]TRIAZIN- -2-YL)-N-(6-FLUOROPYRIDIN-3-YL)-2-METHYLPYRROLIDINE-2-CARBOXAMIDE - Crystalline forms of (S)-1-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)-N-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide of the formula (I) are provided. Also provided is a pharmaceutical composition comprising one or more crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol, as well as a method of using one or more crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol in the treatment of cancer and other proliferative diseases. | 11-29-2012 |
20130225636 | N-(5S,6S,9R)-5-AMINO-6-(2,3-DIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-CYCLOHEP- TA[B]PYRIDIN-9-YL-4-(2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-1-YL)PIPER- IDINE-1-CARBOXYLATE SALT - Disclosed is a hemisulfate salt of Compound (I): | 08-29-2013 |
20140018321 | IMIDAZOLE PRODRUG LXR MODULATORS - Imidazole prodrugs, pharmaceutically acceptable salts, or isomers thereof, of the invention are disclosed, which are useful as modulators of the activity of liver X receptors (LXR). Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed. | 01-16-2014 |
20140364441 | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- -TETRAHYDROISOQUINOLINE AND USE THEREOF - Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention. | 12-11-2014 |
20150266855 | CRYSTALLINE FORMS OF A FACTOR XIA INHIBITOR - The instant invention provides crystalline forms of (S,E)-4-(2-(3-(3-chloro-2-fluoro-6-(1H-tetrazol-1-yl)phenyl)acryloyl)-5-(4-methyl-2-oxopiperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid and its solvates thereof; processes for the production of such crystalline forms; pharmaceutical compositions comprising such crystalline forms; and methods of treating thromboembolic disorders with such crystalline forms or such pharmaceutical compositions. | 09-24-2015 |
Donna Wei, Belle Mead, NJ US
Patent application number | Description | Published |
---|---|---|
20160130299 | TUBULYSIN ANALOGS AND METHODS OF MAKING AND USE - Tubulysin analogs of the formula (I) | 05-12-2016 |
Donna D. Wei, Belle Mead, NJ US
Patent application number | Description | Published |
---|---|---|
20140135318 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS - Disclosed are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: W and Q and G are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bcl-2 family antiapoptotic proteins for the treatment of cancer; and pharmaceutical compositions comprising such compounds. | 05-15-2014 |
20150225452 | IAP ANTAGONISTS - There are disclosed compounds of formula (I) that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing said compounds. | 08-13-2015 |
20150238558 | IAP ANTAGONISTS - There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention. | 08-27-2015 |
George Z. Wei, North Brunswick, NJ US
Patent application number | Description | Published |
---|---|---|
20160133839 | Light Emitting Hybrid Semiconductors Based on IB-VII Binary Compounds - Inorganic-organic hybrid IB-VII semiconductor compounds, in which a Group IB transition metal halide salt is coordinated with an organic heteroaromatic ligand, wherein at least one ring atom of said heteroaromatic ligand is a heteroatom independently selected from N, O and S and the Group IB metal of the halide salt is coordinated to a ring heteroatom. Also disclosed are semiconductor and light emitting devices comprising these materials, including light emitting diodes, and methods of preparing these materials and devices. | 05-12-2016 |
Guanghua Wei, Somerset, NJ US
Patent application number | Description | Published |
---|---|---|
20120171377 | WAFER CARRIER WITH SELECTIVE CONTROL OF EMISSIVITY - A wafer carrier for use in a chemical vapor deposition apparatus includes at least one region on its outer surface having a substantially different (e.g., lower) emissivity than other regions on the outer surface. The modified emissivity region may be located on the outer edge, the top surface, and/or the bottom surface of the carrier. The region may be associated with one or more wafer pockets of the wafer carrier. The modified emissivity region may be shaped and sized so as to modify the heat transmission through the region, and thereby increase the temperature uniformity across portions of the top surface of the wafer carrier or across individual wafers. The modified emissivity region may be provided by a coating on the outer surface of the wafer carrier. | 07-05-2012 |
20120171870 | WAFER PROCESSING WITH CARRIER EXTENSION - Apparatus for treating wafers using a wafer carrier rotated about an axis is provided with a ring which surrounds the wafer carrier during operation. Treatment gasses directed onto a top surface of the carrier flow outwardly away from the axis over the carrier and over the ring, and pass downstream outside of the ring. The outwardly flowing gasses form a boundary over the carrier and ring. The ring helps to maintain a boundary layer of substantially uniform thickness over the carrier, which promotes uniform treatment of the wafers. | 07-05-2012 |
Guanghua Wei, Dayton, NJ US
Patent application number | Description | Published |
---|---|---|
20130065403 | WAFER CARRIER WITH THERMAL FEATURES - A wafer carrier used in wafer treatments such as chemical vapor deposition has pockets for holding the wafers and support surfaces for supporting the wafers above the floors of the pockets. The carrier is provided with thermal control features such as trenches which form thermal barriers having lower thermal conductivity than surrounding portions of the carrier. These thermal control features promote a more uniform temperature distribution across the wafer surfaces and across the carrier top surface. | 03-14-2013 |
Guobao Wei, Milltown, NJ US
Patent application number | Description | Published |
---|---|---|
20120258178 | DEMINERALIZED BONE MATRIX COMPOSITIONS AND METHODS - Bone matrix compositions and, more specifically, demineralized bone matrix (DBM) having increased osteoinductive capacity and methods for its production are provided. Specifically, DBM derived from cortical bone from the periosteal layer of bone are provided. Compositions comprising a disproportionate amount of DBM prepared from bone derived from the periosteal and/or middle layer of bone are provided. Preparations of and methods of use of periosteal DBM compositions are disclosed. | 10-11-2012 |
20120269892 | IMPLANTABLE COMPOSITIONS AND METHODS FOR PREPARING THE SAME - Methods for forming implantable compositions are provided. In some embodiments, the methods include (i) providing a gel base, (ii) adding water and a hydrating agent to the gel base to form a mixture, (iii) reducing the water content of the mixture; and (iv) adding a delivered material before, during, and/or after step (ii) or (iii). The water content is reduced to about 5% or less by weight of the implantable composition. | 10-25-2012 |
20130136777 | Bone Matrix Compositions and Methods - Osteoinductive compositions and implants having increased biological activities, and methods for their production, are provided. The biological activities that may be increased include, but are not limited to, bone forming; bone healing; osteoinductive activity, osteogenic activity, chondrogenic activity, wound healing activity, neurogenic activity, contraction-inducing activity, mitosis-inducing activity, differentiation-inducing activity, chemotactic activity, angiogenic or vasculogenic activity, and exocytosis or endocytosis-inducing activity. In one embodiment, a method for producing an osteoinductive composition comprises providing partially demineralized bone, treating the partially demineralized bone to disrupt the collagen structure of the bone, and optionally providing a tissue-derived extract and adding the tissue-derived extract to the partially demineralized bone. In another embodiment, an implantable osteoinductive and osteoconductive composition comprises partially demineralized bone, wherein the collagen structure of the bone has been disrupted, and, optionally, a tissue-derived extract. | 05-30-2013 |
20130189338 | BONE FIBERS HAVING EXTENDED LENGTH - Demineralized bone matrix fibers and demineralized bone compositions are provided. Implantable demineralized bone matrix compositions include elongated bone fibers having an average length from about 2 cm to about 6 cm and an aspect ratio from about 50:1 to about 1000:1. The demineralized bone matrix compositions also include a carrier in an amount sufficient to produce a cohesive formable mass. The elongated fibers can easily entangle to provide an improved demineralized bone matrix having increased osteoconductivity. | 07-25-2013 |
20130189344 | HUMAN LUBRICATION GEL - Human lubricating gels, methods and kits for delivering a therapeutic agent to a target tissue site beneath the skin of a patient utilizing human lubricating gel are provided, the human lubricating gel being capable of adhering to the target tissue site and comprising one or more biodegradable formulations containing an effective amount of the therapeutic agent. In various embodiments, the human lubricating gel is sprayable and hardens after contacting the target tissue site. | 07-25-2013 |
20130190891 | BONE DELIVERY SYSTEM - A covering for delivering a substance or material to a surgical site is provided. The covering, with substance provided therein, may be referred to as a delivery system. Generally, the covering may be formed of polymers for providing extended shelf life and/or increased moisture and radiation resistance, and may include a single or multi-compartment structure capable of at least partially retaining a substance provided therein until the covering is placed at a surgical site. Upon placement, the covering may facilitate transfer of the substance or surrounding materials. For example, the substance may be released (actively or passively) to the surgical site. The covering may participate in, control, or otherwise adjust the release of the substance. In various embodiments, the covering may be formed of a biocompatible material and is suitable for a variety of procedure specific uses. | 07-25-2013 |
20130195805 | MODIFICATION OF REACTIVITY OF BONE CONSTRUCTS - A method of enhancing the binding of growth factors and cell cultures to a demineralized allograft bone material which includes applying ex vivo an effective quantity of an ionic force change agent to at least a portion of the surface of a demineralized allograft bone material to produce a binding-sensitized demineralized allograft bone material and implanting the binding-sensitized demineralized allograft bone material into a host bone. The ionic force change agent may include at least one of enzymes, pressure, chemicals, heat, sheer force, oxygen plasma, supercritical nitrogen, supercritical carbon, supercritical water or a combination thereof. A molecule, a cell culture, or a combination thereof is administered to the binding-sensitized demineralized allograft bone material. | 08-01-2013 |
20130280303 | BONE DELIVERY SYSTEM HAVING A THERAPEUTIC AGENT - A covering for delivering a therapeutic agent to a surgical site is provided. The covering may include a single or multi-compartment structure configured to at least partially retain the therapeutic agent until the covering is placed at a surgical site. Upon placement, the covering may facilitate transfer of the therapeutic agent to the surgical site. In some embodiments, the covering comprises an antimicrobial agent, a hemostatic agent, an anti-inflammatory agent, and/or a growth factor. | 10-24-2013 |
20140205674 | METHOD OF PREPARING BONE MATERIAL HAVING ENHANCED OSTEOINDUCTIVITY - Methods for increasing osteoinductivity and/or surface area of bone material are provided. The methods include providing bone material and dehydrating the bone material with a solvent at its critical point. A useful solvent for critical point dehydrating is carbon dioxide. Critical point dehydration resulting in increased osteoinductivity and/or surface area can be applied to many types of bone material including bone particles, bone chips, bone fibers, bone matrices, both demineralized and non-demineralized. An implantable composition having an enhanced osteoinductivity and/or osteoconductivity is also provided. The implantable composition contains demineralized bone matrix dried at critical point of carbon dioxide. Critical point dried fibers of a demineralized bone matrix have a BET value from about 40 m | 07-24-2014 |
20140212471 | BONE FIBER COMPOSITIONS - An osteoinductive implantable composition comprising a mixture of demineralized bone fibers and mineralized bone fibers is provided. The mixture is visible under X ray and remodels more easily than comparable mixtures of demineralized bone matrix and surface demineralized cortical bone chips. The osteoinductive implantable compositions comprises demineralized bone fibers in an amount from about 30 vol % to about 45 vol % and mineralized bone fibers in an amount from about 55 vol % to about 70 vol %. The osteoinductive implantable compositions can be delivered in delivery systems including mesh coverings for administration at surgical sites. A method of treating a bone defect caused by injury, disease, wounds, or surgery utilizing the osteoinductive implantable composition comprising a mixture of demineralized bone fibers and mineralized bone fibers is also provided. | 07-31-2014 |
20140277480 | EXPANDABLE SPINAL IMPLANT SYSTEM AND METHOD - A spinal implant comprises a first member including a wall that defines a first cavity and a second member including a wall defining a second cavity. At least one first expandable bone graft is disposable within the second cavity. The second member is axially translatable relative to the first member between a first configuration and a second, expanded configuration such that at least a portion of the at least one first graft is disposed within the first cavity and the first cavity includes a substantially void portion. At least one second bone graft has a selective configuration and dimension for disposal within the substantially void portion. Systems and methods are disclosed. | 09-18-2014 |
20140302112 | BONE MATRIX COMPOSITIONS AND METHODS - Osteoinductive compositions and implants having increased biological activities, and methods for their production, are provided. The biological activities that may be increased include, but are not limited to, bone forming; bone healing; osteoinductive activity, osteogenic activity, chondrogenic activity, wound healing activity, neurogenic activity, contraction-inducing activity, mitosis-inducing activity, differentiation-inducing activity, chemotactic activity, angiogenic or vasculogenic activity, and exocytosis or endocytosis-inducing activity. In one embodiment, a method for producing an osteoinductive composition comprises providing partially demineralized bone, treating the partially demineralized bone to disrupt the collagen structure of the bone. In another embodiment, an implantable osteoinductive and osteoconductive composition comprises partially demineralized bone, wherein the collagen structure of the bone has been disrupted, and, optionally, a tissue-derived extract. | 10-09-2014 |
20140302129 | HUMAN LUBRICATION GEL - Human lubricating gels, methods and kits for delivering a therapeutic agent to a target tissue site beneath the skin of a patient utilizing human lubricating gel are provided, the human lubricating gel being capable of adhering to the target tissue site and comprising one or more biodegradable formulations containing an effective amount of the therapeutic agent. In various embodiments, the human lubricating gel is sprayable and hardens after contacting the target tissue site. | 10-09-2014 |
20150037386 | COMPOSITIONS AND METHODS FOR PROMOTING BONE FORMATION - A method for promoting bone formation is provided. More specifically, a method for promoting bone formation by promoting osteoclast formation is provided. In one embodiment, an implant comprising an implantable material and an osteoclast stimulating substance is provided. | 02-05-2015 |
20150258245 | METHOD OF DELIPIDATION AND/OR TERMINAL STERILIZATION FOR BONE MATERIAL - Methods for delipidation, viral inactivation and terminal sterilization are provided for bone grafting material. The methods include contacting bone material with an amount of supercritical fluid effective to remove at least lipids and at least contaminants from the bone material, thereby obtaining a terminally sterilized and delipidated bone material. In various embodiments, the substantially terminally sterilized and delipidated bone material is 99.0%, 99.5% or 99.9% free of lipids and contaminants. Contaminants that are removed from bone material by terminal sterilization with supercritical fluid include infectious organisms, such as bacteria, viruses, protozoa, parasites, fungi and mold. Bone material or bone compositions that can be treated with critical or supercritical fluids comprise mineralized or demineralized bone particles, mineralized or demineralized bone matrix, partially demineralized bone matrix or combinations thereof. | 09-17-2015 |
20150343114 | BONE DELIVERY SYSTEM HAVING A THERAPEUTIC AGENT - A covering for delivering a therapeutic agent to a surgical site is provided. The covering may include a single or multi-compartment structure configured to at least partially retain the therapeutic agent until the covering is placed at a surgical site. Upon placement, the covering may facilitate transfer of the therapeutic agent to the surgical site. In some embodiments, the covering comprises an antimicrobial agent, a hemostatic agent, an anti-inflammatory agent, and/or a growth factor. | 12-03-2015 |
20160038207 | SEGMENTED DELIVERY SYSTEM - A covering for delivering a substance or material to a surgical site is provided. The covering, with substance provided therein, may be referred to as a delivery system. Generally, the covering may be a single or multi-compartment structure capable of at least partially retaining a substance provided therein until the covering is placed at a surgical site. Upon placement, the covering may facilitate transfer of the substance or surrounding materials. For example, the substance may be released (actively or passively) to the surgical site. The covering may participate in, control, or otherwise adjust the release of the substance. In various embodiments, the covering may be formed of a collagen material and is suitable for a variety of procedure specific uses. | 02-11-2016 |
20160135962 | EXPANDABLE SPINAL IMPLANT SYSTEM AND METHOD - A spinal implant comprises a first member including a wall that defines a first cavity and a second member including a wall defining a second cavity. At least one first expandable bone graft is disposable within the second cavity. The second member is axially translatable relative to the first member between a first configuration and a second, expanded configuration such that at least a portion of the at least one first graft is disposed within the first cavity and the first cavity includes a substantially void portion. At least one second bone graft has a selective configuration and dimension for disposal within the substantially void portion. Systems and methods are disclosed. | 05-19-2016 |
Guo-Qing Wei, Princeton Junction, NJ US
Patent application number | Description | Published |
---|---|---|
20090221881 | METHOD AND SYSTEM FOR INTELLIGENT QUALITATIVE AND QUANTITATIVE ANALYSIS OF DIGITAL RADIOGRAPHY SOFTCOPY READING - The present invention describes a method and system for intelligent diagnostic relevant information processing and analysis. Information associated with a patient is processed via an image reading platform. Based on such processed information, a matrix of diagnosis decisions containing diagnostic related information is generated via a matrix of diagnosis decision platform. A diagnostic decision is made based on the diagnostic relevant information. The image reading platform and/or the matrix of diagnosis decision platform encapsulate information and toolkits to be used to manipulate the information. | 09-03-2009 |
Hong Wei, Lawrenceville, NJ US
Patent application number | Description | Published |
---|---|---|
20130044200 | SYSTEM AND APPARATUS FOR THE CALIBRATION AND MANAGEMENT OF COLOR IN MICROSCOPE SLIDES - A system and apparatus for the color calibration of images recorded through a microscope. An integrated color calibration target microscope slide device and specimen are recorded with an imaging device that acquires both the color values of the specimen and the color values of the color calibration target under a plurality of illuminations and trans-illuminations. A composite image is formed to provide a spectral estimation of the relevant color values of the image. The image is converted into multi-stimulus values governed by a plurality of illuminating conditions. The multi-stimulus values are used to provide image calibration data so that color values of the image, when displayed on a display devices, are faithfully reproduced. | 02-21-2013 |
20130322750 | METHOD AND APPARATUS FOR EVALUATING COLOR IN AN IMAGE - A method for evaluating a color of a sample includes acquiring a color calibrated swatch of the sample, the color calibrated swatch comprising a plurality of pixels, and comparing all pixels that are of a first color in a swatch of a standard to all of the plurality of pixels that are of a second color, wherein the second color is a color in the swatch of the sample that is most similar to the first color in the swatch of the standard. | 12-05-2013 |
20140055592 | SYSTEM AND APPARATUS FOR COLOR CORRECTION IN TRANSMISSION-MICROSCOPE SLIDES - The present invention concerns a system and method for calibration and adjustment of the pixel color values represented within a digital image of a sample by a transmission microscope. Furthermore the present invention is directed to providing sufficient color information in order to generate a color mapping matrix that allows for the creation of a synthetic image to depict the sample under a desired illumination. The system and method provides a solution that generates a destination-device independent image that is configurable to any calibrated display device. | 02-27-2014 |
20140300725 | SYSTEM AND METHOD FOR COLOR CORRECTION OF A MICROSCOPE IMAGE WITH A BUILT-IN CALIBRATION SLIDE - A system and method are disclosed for correcting the color of microscope images for different illuminants. The system includes a microscope having at least one image setting value selector with a plurality of pre-set positions, and an optical train having a distal end and a proximal end and being configured to convey illumination. The optical train is further configured to allow introduction of a calibration slide into the optical train of the microscope at a plurality of possible positions, each position being a conjugate plane of the sample plane, when the sample is in focus. The calibration slide incorporates an integral transmission filter array of known transmission values. | 10-09-2014 |
Hong Wei, Princeton, NJ US
Patent application number | Description | Published |
---|---|---|
20150103401 | REFERENCE COLOR SLIDE FOR USE IN COLOR CORRECTION OF TRANSMISSION-MICROSCOPE SLIDES - The present invention is a microscope slide apparatus and method of use thereof, wherein the slide has an integrated color calibration array of filter elements, each element having a given dimension, each element also having a known transmission spectrum. The complete filter array is observable in the field of view of a microscope under at least one magnification setting of a microscope. The invention further characterized with a secondary integrated filter array that is completely observable at a second magnification setting. | 04-16-2015 |
20150124072 | SYSTEM AND METHOD FOR COLOR CORRECTION OF A MICROSCOPE IMAGE - A system and method for correcting the color of microscope images is described wherein a microscope, equipped with a variable light source and at least one microscope setting selector operates in conjunction with an image recording device having at least one image setting selector with a plurality of settings, and is configured to record at least one white balanced sample image of a sample. The system and method also includes the use of at least one white balanced calibration image of an integral transmissive color filter array of known transmission values in combination with an image processor executing code in order to color calibrate the sample images based on the calibration image. | 05-07-2015 |
20150198522 | METHOD AND APPARATUS FOR IMAGE-BASED COLOR MEASUREMENT USING A SMART PHONE - An apparatus for assisting in measuring a color of a target includes an enclosed housing having a first aperture formed in a first end and a second aperture formed in an opposite second end and aligned concentrically with the first aperture, an array of light emitting diodes positioned inside the housing, between the first aperture and the second aperture, and an array of reference colors having known reflectance spectra, the array of reference colors being removably positioned inside the housing, between the array of light emitting diodes and the second aperture. | 07-16-2015 |
Huafeng Wei, Cherry Hill, NJ US
Patent application number | Description | Published |
---|---|---|
20120130264 | NASAL AIR JET INSUFFLATOR - The present invention provides an apparatus for nasally delivering a supraglottic jet ventilation and methods of treating breathing disorders by utilizing the apparatus for nasally delivering a supraglottic jet ventilation. | 05-24-2012 |
20150320957 | NASAL PULSATILE OXYGENATION AND VENTILATION AIRWAY - The invention provides an apparatus for nasally delivering a supraglottic jet oxygenation and ventilation. The invention also provides methods of utilizing the apparatus for nasally delivering supraglottic jet oxygenation and ventilation. | 11-12-2015 |
Huanyu Wei, Fair Lawn, NJ US
Patent application number | Description | Published |
---|---|---|
20090253805 | Photocurable Thiol-Ene Low Gas Permeability Membranes - The present invention provides modified multifunctional thiol-ene monomers wherein one or more thiols are reacted with a Michael addition reactive double bond compound. The present invention further discloses photocurable thiol-ene formulations comprising thiol-ene monomers including the modified multifunctional thiols. The present invention further discloses photocurable thiol-ene formulations comprising thiol-ene monomers and Michael addition reactive double bond molecules and a Michael catalyst. The formulations of the present invention can be photocured to make films or coatings. In a further disclosure, the formulations, including those comprised of unmodified multifunctional thiols and multifunctional enes, are photocured to form films applied to non-flexible or flexible polymer or non-polymer substrates suitable for food packaging, electronic products, optical products and other applications and free-standing films. The present invention further discloses photocurable thiol-ene formulations comprising thiol-ene monomers and Michael addition reactive double bond molecules and a Michael catalyst. These formulations are disclosed to form free-standing films and coatings on substrates when applied to flexible substrates. Such materials are suitable for use in the packaging of food products and other products which are to be maintained in a hermetically sealed relationship to the atmosphere. | 10-08-2009 |
20130065467 | Substrate Printed with a Water-Based Urethane Printing Ink with Improved Performance Properties - A substrate has a surface printed with an ink or coating composition with excellent adhesion and dry rub resistance, and very good oil and saline rub resistance (crock) properties using a multi-functional carbodiimide as a crosslinker for nonwoven substrates. The rub performance of the ink or coating printed on a nonwoven substrate has been found to be superior to that of a first Sun benchmark ink including pigments for four color printing. In another embodiment, a carbodiimide crosslinker such as multifunctional Carbodilite SV-02 is added to the compositions to further improve rub resistance (crock) and retain liquid characteristics post inoculation when compared to compositions using aziridine as a crosslinker. In a further embodiment, a thin polyolefin film exemplifying a backsheet of a hygiene product was printed with the same crosslinked ink or coating composition and compared with a second Sun benchmark set of inks. | 03-14-2013 |
20130202860 | CHLORINE-FREE INK AND COATING COMPOSITIONS & A METHOD FOR PRINTING ON UNTREATED POLYOLEFIN FILMS WITH IMPROVED ADHESION - Provided are chlorine-free ink and coating compositions that demonstrate improved adherence when applied to untreated flexible plastic film substrates. The provided compositions eliminate the need for a separate step of pre-treating a plastic film before applying an ink or coating composition. Also provided are methods for producing a printed article using the provided ink and coating compositions and methods of adhering chlorine-free inks or coatings that exhibit improved adhesion characteristics to untreated plastic films. | 08-08-2013 |
20130337185 | SUBSTRATE PRINTED WITH A WATER-BASED URETHANE PRINTING INK WITH IMPROVED PERFORMANCE PROPERTIES - A substrate has a surface printed with an ink or coating composition with excellent adhesion and dry rub resistance, and very good oil and saline rub resistance (crock) properties using a multi-functional carbodiimide as a crosslinker for nonwoven substrates. The rub performance of the ink or coating printed on a nonwoven substrate has been found to be superior to that of a first Sun benchmark ink including pigments for four color printing. In another embodiment, a carbodiimide crosslinker such as multifunctional Carbodilite SV-02 is added to the compositions to further improve rub resistance (crock) and retain liquid characteristics post inoculation when compared to compositions using aziridine as a crosslinker. In a further embodiment, a thin polyolefin film exemplifying a backsheet of a hygiene product was printed with the same crosslinked ink or coating composition and compared with a second Sun benchmark set of inks. | 12-19-2013 |
Hui Wei, Princeton Junction, NJ US
Patent application number | Description | Published |
---|---|---|
20130315911 | BISPECIFIC ANTIBODIES AND METHODS OF USING THE SAME - The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same. | 11-28-2013 |
20150072919 | FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND TO MYOSTATIN - The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins. | 03-12-2015 |
20150086552 | BISPECIFIC ANTIBODIES AND METHODS OF USING THE SAME - The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same. | 03-26-2015 |
20150099278 | POLYNUCLEOTIDES ENCODING ANTIBODIES - The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same. | 04-09-2015 |
Junmei Wei, Berkeley Heights, NJ US
Patent application number | Description | Published |
---|---|---|
20090193796 | GASOLINE ENGINE EMISSIONS TREATMENT SYSTEMS HAVING PARTICULATE TRAPS - Provided are exhaust systems and components suitable for use in conjunction with gasoline direct injection (GDI) engines to capture particulates in addition to reducing gaseous emission such as hydrocarbons, nitrogen oxides, and carbon monoxides. Exhaust treatment systems comprising a three-way conversion (TWC) catalyst located on a particulate trap are provided. An exemplary particulate trap is a soot filter. Additional treatment components can be added downstream of the particulate trap, including NO | 08-06-2009 |
20120180464 | Three Way Conversion Catalyst With Alumina-Free Rhodium Layer - Provided are exhaust systems and components suitable for use in conjunction with gasoline engines to treat gaseous emissions such as hydrocarbons, nitrogen oxides, and carbon monoxides. Layered three-way conversion (TWC) catalysts comprise an outer layer whose rhodium is supported by an oxygen storage component, such as a ceria-zirconia composite, and the outer layer is substantially free from alumina as a support. The rhodium-containing layer can be free of all other precious metals, such as platinum and palladium. A lower palladium layer is provided where the palladium is supported by a refractory metal oxide. The lower palladium layer can be free of rhodium and platinum and can contain an oxygen storage component that is the same or different from that in the rhodium-containing layer. Methods of making and using these catalysts are also provided. | 07-19-2012 |
Lan Wei, Berkeley Heights, NJ US
Patent application number | Description | Published |
---|---|---|
20130123237 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS - Novel compounds of structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension. | 05-16-2013 |
20150197516 | NOVEL BENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES - Novel compounds described herein are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPKactivated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension. | 07-16-2015 |
20150203487 | NOVEL AZABENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES - Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension. | 07-23-2015 |
20150210685 | NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES - Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPKactivated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension. | 07-30-2015 |
20150218149 | NOVEL BENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES - Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension. | 08-06-2015 |
20150218183 | NOVEL BENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES - The novel benzimidazole hexahydrofuro[3,2-B]furan derivatives of the present invention are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension. | 08-06-2015 |
20150284411 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[E,2-B]FURAN DERIVATIVES - Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension. | 10-08-2015 |
Lan Wei, Edison, NJ US
Patent application number | Description | Published |
---|---|---|
20120108595 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS - Cyclohexyl sulfonamide compounds which are platelet-activating factor (PAF) receptor antagonists. Said compounds may be useful, for example, for the treatment of atherosclerosis or other PAF-mediated disorders, including inflammatory, cardiovascular, and immune disorders. | 05-03-2012 |
20120277240 | SUBSTITUTED AMINOTETRAHYDROTHIOPYRANS AND DERIVATIVES THEREOF AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES - The present invention is directed to novel substituted aminotetrahydrothiopyrans and derivatives thereof of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 11-01-2012 |
Linli Wei, Bridgewater, NJ US
Patent application number | Description | Published |
---|---|---|
20080227777 | Pyrazolopyridine derivatives as inhibitors of beta-Adrenergic Receptor Kinase 1 - The invention relates to 6-amido substituted pyrazolopyridine derivatives of the formula (I) | 09-18-2008 |
Linli Wei, Whitehouse Station, NJ US
Patent application number | Description | Published |
---|---|---|
20100234356 | COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS - The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula I are provided: | 09-16-2010 |
Qian Wei, Delran, NJ US
Patent application number | Description | Published |
---|---|---|
20100105099 | TRI-FUNCTIONALIZED CRYPTOPHANE, SYNTHESIS AND USES THEREOF - This invention relates to biosensors with improved solubility and affinity to a noble element. Specifically, the invention relates to methods and systems for the detection of target entities using the signal observed in a noble element complexed to the biosensor. | 04-29-2010 |
20110104075 | 129Xe BIOSENSORS AND THEIR USE - This invention relates to enzyme-sensitive biosensors and methods and kits using the same. Specifically, the invention relates to methods, systems and kits for the detection of enzymes using the chemical shift observed in an isotope complexed to the biosensor resulting from a change in the biosensor as the result of the enzyme's activity. | 05-05-2011 |
Ronnie Wei, Bridgewater, NJ US
Patent application number | Description | Published |
---|---|---|
20140348832 | INHIBITORS OF T-CELL ACTIVATION - The present invention provides a bispecific biologic comprising a ligand specific for CTLA-4 and a ligand specific for a pMHC complex. | 11-27-2014 |
Wenlong Wei, Mercerville, NJ US
Patent application number | Description | Published |
---|---|---|
20090119556 | METHOD AND APPARATUS FOR TESTING LOGIC CIRCUIT DESIGNS - Disclosed is a logic testing system that includes a decompressor and a tester in communication with the decompressor. The tester is configured to store a seed and locations of scan inputs and is further configured to transmit the seed and the locations of scan inputs to the decompressor. The decompressor is configured to generate a test pattern from the seed and the locations of scan inputs. The decompressor includes a first test pattern generator, a second test pattern generator, and a selector configured to select the test pattern generated by the first test pattern generator or the test pattern generated by the second test pattern generator using the locations of scan inputs. | 05-07-2009 |
20090119563 | METHOD AND APPARATUS FOR TESTING LOGIC CIRCUIT DESIGNS - Disclosed is a logic testing system that includes a decompressor and a tester in communication with the decompressor. The tester is configured to store a seed and locations of scan inputs and is further configured to transmit the seed and the locations of scan inputs to the decompressor. The decompressor is configured to generate a test pattern from the seed and the locations of scan inputs. The decompressor includes a first test pattern generator, a second test pattern generator, and a selector configured to select the test pattern generated by the first test pattern generator or the test pattern generated by the second test pattern generator using the locations of scan inputs. | 05-07-2009 |
William S. Wei, Belle Mead, NJ US
Patent application number | Description | Published |
---|---|---|
20080287412 | THERAPEUTIC COMBINATION OF AMLODIPINE AND BENAZEPRIL/BENAZEPRILAT - The present invention especially relates to the use of a combination comprising | 11-20-2008 |
William S. Wei, Belle Meade, NJ US
Patent application number | Description | Published |
---|---|---|
20100260004 | DEVICE AND SYSTEM FOR MIXING AND DISPENSING COMPONENTS STORED SEPARATELY FROM ONE ANOTHER - Mixing devices and systems are disclosed for storing separate components and for mixing and dispensing those components on demand. A mixing device includes a syringe having a generally tubular housing formed with a mixing chamber. A plunger is fitted to the tubular housing to form a first syringe. A dispensing syringe is releasably connected to the mixing chamber. At this point each syringe holds a desired amount of a mixture component. The contents of one syringe are passed through the mixing chamber to the other syringe, forming a usually incomplete mixture. The mixture is then passed through the mixing chamber to the other syringe. Multiple passes through the mixing chamber are continued until the desired mixing result is achieved, and the mixture material is contained in the second syringe that is used to thereafter dispense desired amounts of the mixture. | 10-14-2010 |
20140163464 | DEVICE AND SYSTEM FOR MIXING AND DISPENSING COMPONENTS STORED SEPARATELY FROM ONE ANOTHER - Mixing devices and systems are disclosed for storing separate components and for mixing and dispensing those Components on demand. A mixing device includes a syringe having a generally tubular housing formed with a mixing chamber. A plunger is fitted to the tubular housing to form a first syringe. A dispensing syringe is releasably connected to the mixing chamber. At this point each syringe holds a desired amount of a mixture component. The contents of one syringe are passed through the mixing chamber to the other syringe, forming a usually incomplete mixture. The mixture is then passed through the mixing chamber to the other syringe. Multiple passes through the mixing chamber are continued until the desired mixing result is achieved, and the mixture material is contained in the second syringe that is used to thereafter dispense desired amounts of the mixture. | 06-12-2014 |
William Shifeng Wei, Belle Mead, NJ US
Patent application number | Description | Published |
---|---|---|
20100196467 | THERAPEUTIC COMBINATION OF AMLODIPINE AND BENAZEPRIL/BENAZEPRILAT - The present invention especially relates to the use of a combination comprising | 08-05-2010 |
20160067266 | STABILIZED COMPOSITION FOR TREATING PSORIASIS - A storage stable ointment of the present invention comprises a vitamin D compound, a corticosteroid, and an N,N-di(C | 03-10-2016 |
William Shifeng Wei, Ringoes, NJ US
Patent application number | Description | Published |
---|---|---|
20160074331 | COMPOSITE STRUCTURAL MATERIAL AND PHARMACEUTICAL COMPOSITION THEREOF - A composite structural material and pharmaceutical composition comprising same, the use of the composite structural material in preparing a sustained release formulation, and a pharmaceutical composition formulation method; the composite structural material comprises a hydrophobic structural material and a hydrophilic structural material; the proportion of the hydrophobic structural material to the hydrophilic structural material ranges from 1:0.01 to 1:5, preferably 1:0.05 to 1:4, more preferably 1:0.1 to 1:3, and most preferably 1:0.4 to 1:2, such as 1:0.4 to 1:1.3. The pharmaceutical composition comprises the composite structural material and one or more active pharmaceutical ingredients, and preferably the proportion of the composite structural material to the active pharmaceutical ingredients ranges from 1:0.01 to 1:8, more preferably 1:0.02 to 1:5, and most preferably 1:0.03 to 1:1, such as 1:0.3 to 1:0.7. | 03-17-2016 |
Xiaodan Wei, Bridgewater, NJ US
Patent application number | Description | Published |
---|---|---|
20110118178 | METHOD OF TREATMENT OF DIABETES TYPE 2 COMPRISING ADD-ON THERAPY TO INSULIN GLARGINE AND METFORMIN - A method for the treatment of diabetes mellitus type 2 comprising administering | 05-19-2011 |
20130296236 | TREATMENT PROTOCOL OF DIABETES TYPE 2 - The present invention refers to a treatment protocol for diabetes type 2 patients. | 11-07-2013 |
Xiaolan Wei, Mahwah, NJ US
Patent application number | Description | Published |
---|---|---|
20140044762 | Wash Resistant Compositions Containing Aminosilicone - Compositions and methods are disclosed for imparting a long-wearing color to keratin fibers, including hair. More specifically, the invention relates to cosmetic compositions and methods for improving retention of particulate materials, such as pigments, on hair to artificially color the hair and/or to impart other aesthetic benefits to the hair. The compositions comprise at least one aminosilicone polymer having at least one diamino functional group, and a functional group equivalent weight (FGEW) from about 1,000 to about 2,000 g/mol and a non-spherical | 02-13-2014 |
20140161505 | Cosmetic Liquid Extractor Comprising Nonionic Polymers - Aqueous liquid compositions are provided, which comprise nonionic polymers, such as polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), or combinations thereof, and which are free of or substantially free of salt-forming groups. The aqueous liquids form solid, flexible films after direct application to skin, and the films may be peeled from the skin to remove adhered keratotic plugs from pores of the skin. The compositions are easily applied to skin, without dripping, with fingers, a brush, or other applicators. | 06-12-2014 |
Xiaoling Wei, Woodbridge, NJ US
Patent application number | Description | Published |
---|---|---|
20090324655 | SUNSCREEN FORMULA VANISHING CREAM - A cosmetic composition is provided which is a vanishing cream structured with 0.5 to 50% by weight of C | 12-31-2009 |
20090324661 | NIACINAMIDE CONTAINING COSMETIC COMPOSITIONS WITH IMPROVED SKINFEEL PROPERTIES - A cosmetic composition is provided which includes niacinamide, a carboxylic acid bearing structurant, and particles of a condensation polymerized polyamide, the polyamide having an amine value no lower than 0.3 and an HLB value of at least 16. The polyamide particles prevent interaction between niacinamide and the carboxylic acid/salt structurant thereby inhibiting skinfeel complexation and/or phase separation that would be adverse to skinfeel. | 12-31-2009 |
20150118273 | NIACINAMIDE CONTAINING COSMETIC COMPOSITIONS WITH IMPROVED SKINFEEL PROPERTIES - A cosmetic composition is provided which includes niacinamide, a carboxylic acid bearing structurant, and particles of a condensation polymerized polyamide, the polyamide having an amine value no lower than 0.3 and an HLB value of at least 16. The polyamide particles prevent interaction between niacinamide and the carboxylic acid/salt structurant thereby inhibiting skinfeel complexation and/or phase separation that would be adverse to skinfeel. | 04-30-2015 |
Xinyi Wei, Princeton, NJ US
Patent application number | Description | Published |
---|---|---|
20080253950 | HYDROTHERMALLY STABLE AG-ZEOLITE TRAPS FOR SMALL OLEFIN HYDROCARBON MOLECULES - A hydrocarbon trap comprises an Ag-zeolite which is heated by a unique steaming regimen. | 10-16-2008 |
20090041643 | Multilayered Catalyst Compositions - A layered three-way conversion catalyst having the capability of simultaneously catalyzing the oxidation of hydrocarbons and carbon monoxide and the reduction of nitrogen oxides is disclosed. Engine exhaust treatment system and methods of using the same are also provided. In one or more embodiments, the catalyst supported on a carrier has three layers, where at least two of the layers are zoned to have an oxygen storage component being present in an upstream zone in an amount that is less than the oxygen storage component present in the downstream zone. | 02-12-2009 |
20090155151 | Methods and Systems Including CO Oxidation Catalyst With Low NO to NO2 Conversion - Catalysts, catalyst systems, and methods for removing ammonia and/or carbon monoxide in flue gases are provided where ammonia is used with a selective catalytic reduction catalyst for reducing oxides of nitrogen. An oxidation catalyst is utilized, which comprises particulate platinum or platinum/palladium dispersed on zirconia particles, the particulate platinum or platinum/palladium having an average particle size less than about 10 nm. The catalyst is effective to convert less than 20% of NO to NO | 06-18-2009 |
20100104491 | Multilayered Catalyst Compositions - A layered three-way conversion catalyst having the capability of simultaneously catalyzing the oxidation of hydrocarbons and carbon monoxide and the reduction of nitrogen oxides is disclosed. Engine exhaust treatment system and methods of using the same are also provided. The catalytic material can be provided in layers such that a larger amount of oxygen storage component is provided in a downstream zone as compared to an upstream zone. For example, the upstream zone can be configured to have one, two, or three layers, and the downstream zone can be independently configured to have one, two, or three layers. In one or more embodiments, the catalyst supported on a carrier has three layers, where at least two of the layers are zoned to have an oxygen storage component being present in an upstream zone in an amount that is less than the oxygen storage component present in the downstream zone. | 04-29-2010 |
20100180581 | DIESEL OXIDATION CATALYST COMPOSITE WITH LAYER STRUCTURE FOR CARBON MONOXIDE AND HYDROCARBON CONVERSION - Provided is a catalyst composition, in particular a diesel oxidation catalyst, for the treatment of exhaust gas emissions, such as the oxidation of unburned hydrocarbons (HC), and carbon monoxide (CO). More particularly, the present invention is directed to a catalyst structure comprising at least two, specifically three distinct layers, at least one of which contains an oxygen storage component (OSC) that is present in a layer separate from the majority of the platinum group metal (PGM) components, such as palladium and platinum. | 07-22-2010 |
20100186375 | Layered Diesel Oxidation Catalyst Composites - Provided are diesel exhaust components where palladium is segregated from a molecular sieve, specifically a zeolite, in a catalytic material. In the catalytic material, therefore, there are at least two layers: a palladium-containing layer that is substantially free of a molecular sieve and a hydrocarbon trap layer that comprises at least one molecular sieve and is substantially free of palladium. The palladium is provided on a high surface area, porous refractory metal oxide support. The catalytic material can further comprise a platinum component, where a minor amount of the platinum component is in the hydrocarbon trap layer, and a majority amount of the platinum component is in the palladium-containing layer. Systems and methods of using the same are also provided. | 07-29-2010 |
20110033353 | Preparation of Diesel Oxidation Catalyst Via Deposition of Colloidal Nanoparticles - The present invention relates to a process for preparing a catalyst, at least comprising the steps of adding a protecting agent to an aqueous solution of a metal precursor to give a mixture (M1), adding a reducing agent to mixture (M1) to give a mixture (M2), adding a support material to mixture (M2) to give a mixture (M3), adjusting the pH of mixture (M3), and separating the solid and liquid phase of mixture (M3). Furthermore, the present invention relates to the catalyst as such and its use as diesel oxidation catalyst. | 02-10-2011 |
20120077669 | Polymer-Assisted Synthesis Of A Supported Metal Catalyst - Described is a process for the preparation of a catalyst comprising the steps of: | 03-29-2012 |
20120079817 | Surface-Coated Zeolite Materials For Diesel Oxidation Applications - A diesel oxidation catalyst for the treatment of exhaust gas emissions, such as the oxidation of unburned hydrocarbons (HC) and carbon monoxide (CO) is described. Also described is a novel washcoat composition including a surface-coated zeolite coated with at least one of zirconia and alumina, and a platinum group metal supported on a high surface area alumina. | 04-05-2012 |
20120124975 | Diesel Oxidation Catalyst Articles And Methods Of Making And Using - Diesel oxidation catalysts, catalytic articles, methods of making catalytic articles, emissions treatment systems and methods of treating an exhaust gas stream using the catalytic articles for the treatment of exhaust gas emissions, such as the oxidation of unburned hydrocarbons (HC) and carbon monoxide | 05-24-2012 |
20130084222 | Diesel Oxidation Catalyst with Layered Structure Containing Ceria Composition as Palladium Support Material for Enhanced HC and CO Gas Conversion - The present invention relates to a layered diesel oxidation catalyst (DOC) comprising: a) a carrier substrate; b) a diesel oxidation catalytic material comprising b1) a first layer located on the carrier substrate, the first layer comprising palladium impregnated on a support material comprising ceria in an amount of at least 45 weight-% based on the total weight of the support material, and optionally comprising platinum; b2) a second layer located on the first layer, the second layer comprising palladium and platinum each impregnated on a support material comprising a metal oxide; wherein the platinum to palladium weight ratio of the first layer is lower than the platinum to palladium weight ratio of the second layer. | 04-04-2013 |
20130172177 | SINTERING-STABLE HETEROGENEOUS CATALYSTS - A catalyst comprising (i) a support, (ii) metal particles and (iii) a shell which is arranged between the metal particles, wherein the shell (iii) comprises silicon oxide. | 07-04-2013 |
20140044627 | Preparation of Diesel Oxidation Catalyst Via Deposition of Colloidal Nanoparticles - The present invention relates to a process for preparing a catalyst, at least comprising the steps of adding a protecting agent to an aqueous solution of a metal precursor to give a mixture (M1), adding a reducing agent to mixture (M1) to give a mixture (M2), adding a support material to mixture (M2) to give a mixture (M3), adjusting the pH of mixture (M3), and separating the solid and liquid phase of mixture (M3). Furthermore, the present invention relates to the catalyst as such and its use as diesel oxidation catalyst. | 02-13-2014 |
20140260214 | NOx Storage Catalyst with lmproved Hydrothermal Stability and NOx Conversion | 09-18-2014 |
20140360171 | Catalyst With Improved Hydrothermal Stability - A catalyst for the treatment of exhaust gas emissions is disclosed. The catalyst can comprise ceria-alumina particles having a ceria phase present in a weight percent of the composite in the range of about 20% to about 80% on an oxide basis, an alkaline earth metal component supported on the ceria-alumina particles, wherein the CeO | 12-11-2014 |
Yuan Wei, North Brunswick, NJ US
Patent application number | Description | Published |
---|---|---|
20100168385 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED AMINO-ALCOHOLS - A process for preparing an enantiomerically enriched amino alcohol or derivatives thereof having the structure: | 07-01-2010 |
Yuchien Wei, Plainsboro, NJ US
Patent application number | Description | Published |
---|---|---|
20150110277 | Wearable/Portable Device and Application Software for Alerting People When the Human Sound Reaches the Preset Threshold - The present invention relates generally to a portable/wearable device as well as application or a software program to be downloaded onto a mobile device or computer. The present invention is intended to measure sound intensity/level and provide an alert signal to remind user(s) or crowds (i.e groups of people) that they are speaking too loud or making too much noise. Furthermore, optionally, the device may play a pre-selected music or pre-recorded message when the sound level threshold is exceeded, which can encourage all of the users to use the bio-feedback of the present invention to relax when they see the visual que such as the light color changes, hear the music, message or produced from the device. Another object of the present invention is to help people to know whether his/her voice is loud enough to be heard by people who have hearing impairment. | 04-23-2015 |
Zhi Wei, Princeton, NJ US
Patent application number | Description | Published |
---|---|---|
20120309639 | Compositions and Methods for Diagnosing Genome Related Diseases and Disorders - Compositions, methods, and kits for diagnosing genetic disorders such as type I diabetes are disclosed. | 12-06-2012 |